The Week

Viking Therapeutics (VKTX) fell 11.72% for the week to $25.17, versus a 1.95% decline in the S&P 500, underperforming by 9.77 percentage points. The week was choppy: the stock touched $28.84 on Monday, dropped 5.96% on Tuesday on heavy volume, and slid another 7.66% on Friday to end at $25.17, just above the week low of $24.94. Weekly volume was 28.0m shares, with the average daily volume 153.63% above the 60-day median.

Key Events

This week’s news was dominated by VK2735 oral development. On Monday, Oppenheimer issued a highly bullish note with a $120 target. On Wednesday, the company announced the initiation of the VK2735 oral Phase 3 clinical programme in obesity patients, and H.C. Wainwright reiterated its buy rating. Later the same day, Viking issued a correction to the dosing schedule statement for the VK2735 oral maintenance trial. The pullback came alongside broad large-order activity in healthcare names.

Analyst Ratings

A total of 21 firms cover VKTX: 14 rate it buy, 5 overweight and 2 hold, with no underweight or sell ratings. The consensus rating is strong buy, and the consensus target price of $94.5 sits 275.45% above the current price of $25.17. The target range of $38 to $125 reflects wide dispersion across brokers. VKTX ranks 25th out of 509 companies in the biotechnology industry peer rating league.

The Week Ahead

Next week’s macro calendar is housing-focused: Monday brings the NAHB housing market index (prior 32, forecast 32); Tuesday sees housing starts annualised (prior 1.275, forecast 1.305) and building permits annualised (prior 1.403, forecast 1.395). Wednesday includes EIA weekly crude oil and Cushing inventory data. On the company side, the next signals will be patient enrolment progress and any interim updates from the VK2735 oral Phase 3 programme.

In Short

VKTX gave back last week’s gains and set a 60-day closing low. Analysts used ratings and targets to signal confidence in the clinical story, while large-lot money turned net seller on the latest session and volume expanded as the price fell. The read-through is one of widening tension: the Street’s views and the tape’s direction diverge. Macro housing prints and the pace of clinical execution are the next things to watch.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.